Utilization management and review

This section is internal utilization-management criteria; automated approvals may be used but all denials require licensed clinician review.

CAR‑T coding and high‑cost therapy mapping

CAR‑T and other high-cost cellular immunotherapies are mapped to DRG 018 and HCPCS codes Q2041–Q2042, Q2053–Q2056; these items represent high-cost therapies and may require prior authorization or special handling.

• Mapped MS‑DRG: DRG 018 (CAR‑T and Other Immunotherapies).
• HCPCS: Q2041, Q2042, Q2053, Q2054, Q2055, Q2056.

Always‑inpatient treatments (apply inpatient authorization)

Indications that should always be managed as inpatient include induction chemotherapy (AML/ALL), stem‑cell transplant conditioning through engraftment, and CAR‑T lymphodepletion through the CRS monitoring period.

• Authorize as inpatient when documentation supports induction chemotherapy (AML/ALL).
• Authorize as inpatient for HSCT conditioning through engraftment.
• Authorize as inpatient for CAR‑T lymphodepletion through CRS monitoring period.

Inpatient‑required therapies — authorization required

Admissions for induction chemotherapy (AML/ALL), HSCT conditioning through engraftment, and CAR‑T lymphodepletion require inpatient authorization when documented.

• Document treatment plan and SI/IS criteria to support inpatient authorization.

Admission requires SI and/or IS criteria

Admission requires demonstration of Severity of Illness (SI) (all SI elements) and at least one Intensity of Service (IS) element to meet inpatient criteria.

• SI: active oncologic condition requiring inpatient monitoring; complication not manageable outpatient; clinical severity requiring continuous monitoring; expected ≥2 midnights.
• IS (≥1): multi‑day continuous IV chemo not available outpatient; daily labs; transfusion support (≥2 units or daily platelet need); IV meds needing inpatient monitoring; HEPA neutropenic precautions; ICU‑level monitoring for complications.

Prior authorization — admission criteria must be documented

Prior authorization for inpatient admission requires documentation that the member meets SI and/or IS criteria such as need for multi‑day continuous IV chemotherapy unavailable outpatient, daily laboratory monitoring, transfusion support, or ICU‑level monitoring.

• Ensure the record documents which SI/IS elements are met and the treatment plan.
• For CAR‑T/HSCT, include expected monitoring needs and anticipated ≥2‑midnight stay where applicable.

Step therapy

No step‑therapy requirements are specified in this excerpt.

Intensity‑of‑Service admission requirements

Intensity‑of‑Service criteria must be met to justify inpatient admission (examples: multi‑day continuous IV chemotherapy not available outpatient; daily lab monitoring; blood transfusion support; IV medications requiring inpatient monitoring; HEPA room; ICU‑level monitoring).

• At least one IS element must be documented to support inpatient level of care.

Daily monitoring and concurrent review requirements

Daily oncology review is required for continued inpatient stay and must document active treatment and daily progress; for induction chemotherapy this includes daily CBC with ANC nadir/recovery tracking, for transplant daily engraftment assessment, and for CAR‑T daily CRS/ICANS grading.

• Document daily CBC/ANC for induction chemo (track nadir and recovery).
• Document daily engraftment assessments for HSCT.
• Document daily CRS/ICANS grading (ASTCT) for CAR‑T patients.

Billing crosswalk guidance (MS‑DRG / revenue codes)

MS‑DRG and revenue code crosswalks are provided to support billing and level‑of‑care decisions; use the listed DRG groupings (e.g., DRG 091‑093 for neurologic when G89.3 PDx, DRG 014‑017 for HSCT, DRG 018 for CAR‑T) when mapping high‑cost therapies and admissions.

• Map CAR‑T to DRG 018 and listed HCPCS for therapy-level billing.
• Use HSCT DRG 014‑017 for transplant admissions where applicable.

Level‑of‑care (LOC) based escalation guidance

Level‑of‑care escalation is tied to objective clinical thresholds: ICU for CRS grade ≥3 or ICANS grade ≥3; stepdown for CRS grade 2 after tocilizumab or ICANS grade 1–2 with frequent neuro checks, etc.

• Escalate to ICU when CRS ≥3 or ICANS ≥3 (vasopressors, ventilator, organ support).
• Consider stepdown/PCU for CRS grade 2 on tocilizumab or hemodynamic concern with febrile neutropenia.

Extended‑stay documentation — required elements

When Goal LOS is exceeded, providers must document one or more specific medical‑necessity triggers, the clinical evidence supporting the trigger, and a targeted intervention plan (e.g., persistent febrile neutropenia despite broad‑spectrum antibiotics; tumor lysis requiring rasburicase or dialysis; mucositis with TPN dependence; persistent CRS/ICANS; graft failure/delayed engraftment).

• Identify and describe the exact extended‑stay trigger.
• Provide clinical data (labs, cultures, imaging) supporting the trigger.
• Document the planned targeted intervention(s) and expected timeline.

Admission documentation requirements

Admission documentation must include the active oncologic condition, the treatment plan, and clinical severity indicators; record which SI and IS elements are met (for example: multi‑day IV chemo required, daily labs, transfusion needs, or ICU‑level monitoring).

• Include treatment plan specifying expected monitoring needs and anticipated LOS (≥2 midnights if expected).
• Document transfusion requirements, ICU needs, and inability to safely manage outpatient.

Extended stay documentation requirements (detail)

When Goal LOS is exceeded the provider must document the specific extended‑stay trigger, supporting clinical evidence, and a targeted intervention plan — one or more of the listed triggers must be present to justify continued stay.

• Examples of triggers: persistent febrile neutropenia, tumor lysis needing rasburicase/dialysis, TPN‑dependent mucositis, persistent CRS/ICANS, graft failure or delayed engraftment beyond expected day +14.

Concurrent review documentation — daily oncology review

Concurrent review requires daily oncology assessment documenting active treatment and daily progress toward milestones; for chemo induction include daily CBC/ANC trends, for transplant daily engraftment measures, and for CAR‑T daily CRS/ICANS grading.

• Daily notes must reference objective data (CBC/ANC, engraftment labs, CRS/ICANS grades) and planned next steps.
• Use documented progress to support continued inpatient status.

Extended‑stay documentation (provider must specify trigger & plan)

Repeated: When Goal LOS is exceeded the provider must document the specific trigger with supporting clinical evidence and a targeted intervention plan to justify continued inpatient stay.

Concurrent review documentation — objective daily monitoring

Concurrent review must document daily oncology review with active treatment and daily progress (examples: daily CBC/ANC for chemo induction; daily engraftment assessment for transplant; daily CRS/ICANS grading for CAR‑T).

• Record objective milestones (ANC trend, transfusion independence, engraftment markers) each day.

Extended‑stay documentation — clinical evidence & intervention plan required

When Goal LOS is exceeded continued inpatient stay requires documentation of one or more specific medical‑necessity triggers, the clinical evidence supporting the trigger, and the targeted intervention plan (documented in the medical record).

Observation vs inpatient decision — denials likely if only cancer diagnosis present

Inpatient admission will not be supported when the only reason is a cancer diagnosis without acute treatment or complication requiring inpatient monitoring; surveillance imaging, staging/workup, elective biopsy, chemotherapy safely given outpatient, or continued stay solely awaiting outpatient scheduling are not sufficient.

• Avoid inpatient coding/authorization when care can be safely provided outpatient.
• Document acute treatment or complication if claiming inpatient necessity.

Admission/stay denial triggers — common denial scenarios

Admissions may be denied when the sole reason is a cancer diagnosis without acute treatment or a complication requiring inpatient monitoring; similarly, admissions for chemotherapy that can be safely administered outpatient or continued stay solely awaiting outpatient scheduling may be denied.

• Ensure documentation shows acute treatment need, IS elements, or SI indicators to avoid denial.

Observation vs inpatient — denial risk when inpatient criteria not met

Admission not meeting inpatient criteria (for example: cancer diagnosis alone without acute treatment/complication, or chemotherapy safely given outpatient) may be denied as inpatient level of care.

• If inpatient status is requested, document which SI/IS criteria are met and the treatment plan.

Observation vs inpatient — denial triggers (examples)

Admissions may be denied when the cancer diagnosis alone is present without acute treatment or complication requiring inpatient monitoring, or when chemotherapy can be safely administered outpatient; continued stay solely awaiting outpatient scheduling is also a denial trigger.

Admission/observation criteria — denial risk summary

Admission may be denied when cancer diagnosis alone without acute treatment or complication is the sole reason, or for continued stay solely awaiting outpatient scheduling while medically stable for discharge.